1. |
News in brief ... |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 296,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
Renal DM a smart investment |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 296,
2001,
Page 3-4
Amanda Cameron,
Preview
|
|
摘要:
There's no doubt about it, end-stage renal disease (ESRD) is a costly, complex disease to manage. It may be less prevalent than other chronic diseases, but its high treatment costs ($US50 000-$US100 000/patient/year) mean that ESRD can cost a 1 million-member health plan > $US50 million annually. At this price, it's no wonder that several managed-care organisations in the US have made ESRD a target for disease management (DM). Indeed, the experiences of these companies - presented at the 2nd Annual Disease Management Leadership Forum*[Baltimore, Maryland, US; November 2000] - indicate that investment in ESRD DM is a canny move, one that not only improves clinical outcomes and member satisfaction, but also produces the hoped-for return on investment.
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Websites could help differentiate HMOs |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 296,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
Cervical cancer screening policies vary greatly in EU |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 296,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
News in brief... |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 296,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
News in brief... |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 296,
2001,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
News in brief... |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 296,
2001,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
Antihypercalcaemics get a break in advanced breast cancer |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 296,
2001,
Page 9-10
Laura Hunt,
Preview
|
|
摘要:
Clinical trial data have shown that the antihypercalcaemic agents pamidronic acid and clodronic acid can reduce the overall incidence of skeletal complications in women with metastatic breast cancer. In addition, both agents delay the onset of skeletal complications, promote bone healing, and have a positive effect on bone pain. Now, 3 economic analyses have found that pamidronic acid and clodronic acid provide substantial benefits at a reasonable cost to the healthcare systems in Italy and Poland. The results of these trials were presented at the ISPOR*3rd Annual European Conference, held in Antwerp, Belgium, in November 2000.
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
Depression adds to diabetes costs, decreases compliance and function |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 296,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
World retail sales of prescription drugs grow 11% over 12 months |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 296,
2001,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|